A phase I inhalation study on ASM-024, a novel nicotinic agonist being developed for the treatment of asthma Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond Source: Eur Respir J, 56 (2) 2001610; 10.1183/13993003.01610-2020 Year: 2020
A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma? Source: Eur Respir Rev 2015; 25: 54-64 Year: 2016
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models Source: Annual Congress 2010 - Models of airways disease Year: 2010
The antitussive effects of alpha7 (a7) nicotinic receptor agonists Source: International Congress 2017 – Novel studies on bronchodilators and cough Year: 2017
A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Nicotinic alpha-7 receptor stimulation (a7nAChR) inhibited NF-kB/STAT3/SOCS3 pathways in a murine model of asthma. Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists Source: Eur Respir Monogr 2020; 88: 238-250 Year: 2020
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Alpha-7 nicotinic receptor stimulation reduces airway inflammation in a murine model of asthma Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016
The novel dual D2 dopamine receptor, β2 -adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Pharmacological treatment of asthma today Source: Eur Respir J 2001; 18: 34S-40S Year: 2001
An oral selective M3 cholinergic receptor antagonist in COPD Source: Eur Respir J 2006 Oct 01;28(4):772-780 Year: 2006
Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007